A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要Background The epidermal growth factor receptor (EGFR) is commonly overexpressed in nasopharyngeal carcinoma (NPC) and gefitinib inhibits NPC growth in vitro.
著者Ma B, Hui EP, King A, To KF, Mo F, Leung SF, Kam M, Lo YMD, Zee B, Mok T, Ahuja A, Chan ATC
期刊名稱Cancer Chemotherapy and Pharmacology
出版年份2008
月份6
日期1
卷號62
期次1
出版社SPRINGER
頁次59 - 64
國際標準期刊號0344-5704
電子國際標準期刊號1432-0843
語言英式英語
關鍵詞epidermal growth factor receptor; gefitinib; nasopharyngeal carcinoma; plasma EBV DNA
Web of Science 學科類別Oncology; ONCOLOGY; Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY

上次更新時間 2020-27-11 於 01:30